Clinical Trials Directory

Trials / Completed

CompletedNCT04116307

Enteroadsorbent Polymethylsiloxane vs Probiotic Lactobacillus Reuteri in the Treatment of Rotaviral Gastroenteritis

Comparison of Clinical Efficacy of Enteroadsorbent Polymethylsiloxane vs Probiotic Lactobacillus Reuteri in the Treatment of Rotaviral Gastroenteritis in Infants and Toddlers.

Status
Completed
Phase
Phase 4
Study type
Interventional
Enrollment
130 (actual)
Sponsor
University Hospital for Infectious Diseases, Croatia · Academic / Other
Sex
All
Age
6 Months – 3 Years
Healthy volunteers
Accepted

Summary

This study evaluates a new drug, new enteroadsorbent polymethylsiloxane (Enterosgel) in the treatment of rotavirus gastroenteritis in children. Half of the participants received a new drug, polymethylsiloxane and half of the participants received standard treatment - probiotic L. reuteri (BioGaia).

Detailed description

Polymethylsiloxane and probiotic L. reuteri both hasten symptoms of the rotavirus gastroenteritis but they do so by a different mode of action. Polymethylsiloxane is an enteroadsorbent and it possibly acts by adsorption of viruses and doing so it prevents binding rotaviruses for enterocytes. Another mode of action can be forming a thin layer over the mucosal surfaces thus protects them from various damaging factors. Probiotics help the healing of the intestinal mucosa presumably in few ways - by normalization of gut flora, by competition with pathogen bacteria for binding sites and nutrients and by stimulation of intestinal immune system.

Conditions

Interventions

TypeNameDescription
DIETARY_SUPPLEMENTPolymethylsiloxane
DIETARY_SUPPLEMENTLactobacillus reuteri

Timeline

Start date
2013-01-01
Primary completion
2017-05-31
Completion
2017-05-31
First posted
2019-10-04
Last updated
2019-10-04

Locations

1 site across 1 country: Croatia

Source: ClinicalTrials.gov record NCT04116307. Inclusion in this directory is not an endorsement.